Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer

Borut Kragelj; Lijana Zaletel-Kragelj; Boris Sedmak; Tanja Cufer; Jozica Cervek

doi:10.1016/j.radonc.2005.01.007

Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer

Radiother Oncol. 2005 Apr;75(1):44-7. doi: 10.1016/j.radonc.2005.01.007. Epub 2005 Apr 18.

Authors

Borut Kragelj¹, Lijana Zaletel-Kragelj, Boris Sedmak, Tanja Cufer, Jozica Cervek

Affiliation

¹ Department of Radiation Therapy, Institute of Oncology, SI-1000 Ljubljana, Slovenia. bjragelj@onko-i.si

PMID: 15878100
DOI: 10.1016/j.radonc.2005.01.007

Abstract

Concurrent vinablastine-based radiochemotherapy was evaluated in 84 bladder-cancer patients. It was effective in more than half: tumour-specific survival (51% 9-year), local control rate (55% 9-year). The drawback was the impaired function of the bladder (9-year prevalence SOMA G3-4 symptoms: 66%), indicating the need for treatment aimed at reducing chronic morbidity.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Agents, Phytogenic / therapeutic use*
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / radiotherapy*
Vinblastine / administration & dosage
Vinblastine / therapeutic use*

Substances

Antineoplastic Agents, Phytogenic
Vinblastine